Benzinga | Oct 4, 2021 08:08AM EDT

Candel Therapeutics Announces Participation In Upcoming Society For Immunotherapy Of Cancer's (SITC) 36th Annual Meeting

Candel Therapeutics, Inc. (NASDAQ:CADL), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today announced that the Company will present novel biomarker data from the ongoing phase 1 clinical trial of CAN-3110 in recurrent high-grade glioma at the Society for Immunotherapy of Cancer's (SITC) 36th Annual Meeting taking place November 10-14, 2021 in Washington D.C., and virtually.



Poster details:

Title: Detection of viral antigen and immune activation after intra-tumor injection of CAN-3110 (ICP-34.5 expressing HSV-1 oncolytic virus) in patients with recurrent high-grade glioma

Abstract Number: 395

Primary Author/Presenter Francesca Barone, MD, PhD, Vice President, Head of Research, Candel Therapeutics, Inc.

Date/Time: November 12, 2021, 7:00 am -- 8:30 pm ET

Full text of the abstract will be released on the SITC website at 8:00 a.m. ET on Tuesday, November 9, 2021. Details from the presentation will be available on the Candel website at https://www.candeltx.com/news/.